Lobe Sciences Ltd. (LOBEF)
OTCMKTS · Delayed Price · Currency is USD
0.0027
-0.0263 (-90.69%)
Jul 15, 2025, 4:00 PM EDT
Lobe Sciences Revenue
In the fiscal year ending August 31, 2024, Lobe Sciences had annual revenue of 136.21K CAD, down -83.80%.
Revenue
136.21K CAD
Revenue Growth
-83.80%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.93M USD
Revenue Chart
* This company reports financials in CAD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Lobe Sciences News
- 8 days ago - Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease - Accesswire
- 4 weeks ago - Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals - Accesswire
- 6 weeks ago - Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth - Accesswire
- 3 months ago - Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM) - Accesswire
- 3 months ago - Lobe Sciences Provides Corporate Update - Accesswire
- 8 months ago - Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™ - Business Wire
- 9 months ago - Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™ - Business Wire
- 10 months ago - Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™ - Business Wire